samedan logo

 
 
spacer
home > white papers > Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products - Entegris
WHITE PAPERS
logo_Entegris.jpg

Entegris

phone +1 978 436 6500
web http://https://www.entegris.com/en/home.html
email 129 Concord Road, Billerica, MA 01821

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.

Many pharmaceuticals — monoclonal antibodies, vaccines, and patient-specific therapeutics — must be reliably stored and transported at sub-zero temperatures, requiring a robust cold chain that contin ues throughout downstream processing (Figure 1). Demand for these pharmaceutical products is on the order of hundreds of kilograms per year and contin ues to increase.1 While large manufacturers are already well-equipped to handle these volumes, it is possible for smaller laboratories to quickly adapt to produce a wide variety of specialized drugs and distribute them without compromising safety or increasing financial risk.
Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Klöckner Pentaplast Launches Its 2020 Sustainability Report

London, UK – 19 July 2021 – Klöckner Pentaplast (kp or the company), a global leader in high barrier protective packaging solutions, today announced the release of its 2020 Sustainability Report, detailing its progress and commitment to key sustainability initiatives. The report provides details of performance relating to topics that are material to its business and has been prepared in accordance with the Global Reporting Initiative (GRI) Standards.
More info >>


White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>


Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement